About Scynexis
Scynexis is a company based in Jersey City (United States) founded in 1999. Scynexis has raised $62.65 million across 9 funding rounds from investors including Société Générale, SLR Investment Corp and Burrill and Company. The company has 28 employees as of December 31, 2024. Scynexis offers products and services including SCY-247 and Ibrexafungerp. Scynexis operates in a competitive market with competitors including F2g, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others.
- Headquarter Jersey City, United States
- Employees 28 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scynexis, Inc.
-
Annual Revenue
$3.75 M (USD)-97.33as on Dec 31, 2024
-
Net Profit
-$21.29 M (USD)-131.75as on Dec 31, 2024
-
EBITDA
-$37.12 M (USD)-150.51as on Dec 31, 2024
-
Total Equity Funding
$62.65 M (USD)
in 9 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Apr 09, 2020
-
Investors
Société Générale
& 10 more
-
Employee Count
28
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scynexis
Scynexis is a publicly listed company on the NASDAQ with ticker symbol SCYX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scynexis
Scynexis offers a comprehensive portfolio of products and services, including SCY-247 and Ibrexafungerp.
Second-generation agent for treating invasive fungal infections
Novel therapy against serious fungal pathogens
People of Scynexis
Unlock access to complete
Unlock access to complete
Funding Insights of Scynexis
Scynexis has successfully raised a total of $62.65M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scynexis
Scynexis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Société Générale, SLR Investment Corp and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Debt and equity investments are offered by the firm.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
Limited information is provided about KBL Healthcare Ventures.
|
Locked | Locked | Locked |
Investor details for Scynexis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scynexis
Investment portfolio details for Scynexis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scynexis
Detailed financials for Scynexis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scynexis Comparisons
Peer comparison for Scynexis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scynexis
Scynexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as F2g, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| Locked | Locked | Locked |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| Locked | Locked | Locked |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
Detailed competitors of Scynexis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scynexis
Complete news archive for Scynexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scynexis
Scynexis was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Scynexis is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Marco Taglietti is the current CEO of Scynexis.
Scynexis is a funded company, having raised a total of $62.65M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Scynexis is 28.
Annual revenue of Scynexis is $3.75M as on Dec 31, 2024.
Developing glucan synthase inhibitors for the treatment of fungal infections. The companys lead candidate is SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections. SCY-078 acts as a glucan synthase inhibitor against a broad range of Candida and Aspergillus species.
Scynexis's top competitors include F2g, Amplyx Pharmaceuticals and Biosergen.
Scynexis offers SCY-247 and Ibrexafungerp.
Yes, Scynexis is publicly traded on NASDAQ under the ticker symbol SCYX.
Scynexis has 11 investors. Key investors include Société Générale, SLR Investment Corp, Burrill and Company, Merial, and Puissance Capital.
The ticker symbol of Scynexis is SCYX on NASDAQ.